BRPI0512854A - terapia adjuvante aperfeiçoada para tumores que expressam g250 - Google Patents
terapia adjuvante aperfeiçoada para tumores que expressam g250Info
- Publication number
- BRPI0512854A BRPI0512854A BRPI0512854-4A BRPI0512854A BRPI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A BR PI0512854 A BRPI0512854 A BR PI0512854A
- Authority
- BR
- Brazil
- Prior art keywords
- adjuvant therapy
- expressing tumors
- improved adjuvant
- antigen
- improved
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000009098 adjuvant therapy Methods 0.000 title 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 abstract 3
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000683 nonmetastatic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
TERAPIA ADJUVANTE APERFEIçOADA PARA TUMORES QUE EXPRESSAM G250. A invenção refere-se a um método para tratamento de tumores que expressam o antígeno G250, em particular carcinoma renal de células claras compreendendo a administração de anticorpos específicos para o antígeno G250 em pacientes de alto risco diagnosticados com doença não metastática.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58467904P | 2004-07-02 | 2004-07-02 | |
PCT/EP2005/006994 WO2006002889A2 (en) | 2004-07-02 | 2005-06-29 | Improved adjuvant therapy of g250-expressing tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0512854A true BRPI0512854A (pt) | 2008-04-08 |
Family
ID=35431139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0512854-4A BRPI0512854A (pt) | 2004-07-02 | 2005-06-29 | terapia adjuvante aperfeiçoada para tumores que expressam g250 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7691375B2 (pt) |
EP (2) | EP1763367A2 (pt) |
JP (1) | JP2008505143A (pt) |
KR (1) | KR101205289B1 (pt) |
CN (1) | CN101052416B (pt) |
AU (1) | AU2005259481B2 (pt) |
BR (1) | BRPI0512854A (pt) |
CA (1) | CA2566950A1 (pt) |
DK (1) | DK2497497T3 (pt) |
ES (1) | ES2641089T3 (pt) |
MX (1) | MXPA06013240A (pt) |
RU (2) | RU2371198C2 (pt) |
WO (1) | WO2006002889A2 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077081A1 (en) * | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
AU2003280442B2 (en) * | 2002-07-01 | 2009-02-05 | Wilex Ag | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
CA2774421A1 (en) | 2009-09-18 | 2011-03-24 | Mitsubishi Chemical Corporation | Hepatocellular carcinoma marker |
RU2442983C1 (ru) * | 2011-01-14 | 2012-02-20 | Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции |
ME03486B (me) | 2012-10-12 | 2020-01-20 | Medimmune Ltd | Pirolobenzodiazepini i njihovi konjugati |
JP2016511766A (ja) * | 2013-02-22 | 2016-04-21 | ウィレックス・アーゲー | Caix階層化に基づく癌治療 |
CN105209077B (zh) | 2013-03-13 | 2019-06-11 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓以及其结合物 |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドMedImmune Limited | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
MX2020012418A (es) | 2018-05-23 | 2021-04-28 | Adc Therapeutics Sa | Adyuvante molecular. |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0366707A1 (en) | 1987-05-06 | 1990-05-09 | OOSTERWIJK, Egbert | Monoclonal antibodies to renal cell carcinoma |
US5387676A (en) | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
EP1358318B8 (en) | 2001-02-07 | 2006-11-15 | Wilex AG | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
ATE509032T1 (de) | 2002-02-13 | 2011-05-15 | Ludwig Inst For Cancer Res Ltd | Chimerizierte gm-csf antikörper |
AU2003280442B2 (en) * | 2002-07-01 | 2009-02-05 | Wilex Ag | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas |
-
2005
- 2005-06-29 EP EP05775970A patent/EP1763367A2/en not_active Ceased
- 2005-06-29 AU AU2005259481A patent/AU2005259481B2/en active Active
- 2005-06-29 CA CA002566950A patent/CA2566950A1/en not_active Abandoned
- 2005-06-29 DK DK12171081.8T patent/DK2497497T3/en active
- 2005-06-29 RU RU2007104040/14A patent/RU2371198C2/ru not_active IP Right Cessation
- 2005-06-29 MX MXPA06013240A patent/MXPA06013240A/es active IP Right Grant
- 2005-06-29 EP EP12171081.8A patent/EP2497497B1/en active Active
- 2005-06-29 US US11/630,170 patent/US7691375B2/en active Active
- 2005-06-29 CN CN2005800205034A patent/CN101052416B/zh not_active Expired - Fee Related
- 2005-06-29 BR BRPI0512854-4A patent/BRPI0512854A/pt not_active Application Discontinuation
- 2005-06-29 ES ES12171081.8T patent/ES2641089T3/es active Active
- 2005-06-29 JP JP2007519679A patent/JP2008505143A/ja active Pending
- 2005-06-29 KR KR1020067027704A patent/KR101205289B1/ko active IP Right Grant
- 2005-06-29 WO PCT/EP2005/006994 patent/WO2006002889A2/en active Application Filing
-
2009
- 2009-06-10 RU RU2009122344/15A patent/RU2519340C2/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK2497497T3 (en) | 2017-08-14 |
US20070207157A1 (en) | 2007-09-06 |
WO2006002889A3 (en) | 2006-10-05 |
WO2006002889A2 (en) | 2006-01-12 |
EP2497497A1 (en) | 2012-09-12 |
JP2008505143A (ja) | 2008-02-21 |
AU2005259481A1 (en) | 2006-01-12 |
CN101052416A (zh) | 2007-10-10 |
KR20070036085A (ko) | 2007-04-02 |
US7691375B2 (en) | 2010-04-06 |
CN101052416B (zh) | 2013-07-10 |
AU2005259481B2 (en) | 2010-04-22 |
RU2371198C2 (ru) | 2009-10-27 |
MXPA06013240A (es) | 2007-02-28 |
EP1763367A2 (en) | 2007-03-21 |
KR101205289B1 (ko) | 2012-11-27 |
CA2566950A1 (en) | 2006-01-12 |
ES2641089T3 (es) | 2017-11-07 |
EP2497497B1 (en) | 2017-06-21 |
RU2009122344A (ru) | 2010-12-20 |
RU2519340C2 (ru) | 2014-06-10 |
RU2007104040A (ru) | 2008-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0512854A (pt) | terapia adjuvante aperfeiçoada para tumores que expressam g250 | |
NO20084479L (no) | Antitumor celleantigen antistoff terapi | |
CY2017013I1 (el) | ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ | |
BRPI0916138A2 (pt) | "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito" | |
CL2008001258A1 (es) | Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria. | |
ECSP088733A (es) | Anticuerpos anti-5t4 y usos de los mismos | |
NO20064193L (no) | fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser | |
CR9512A (es) | Metodos para el tratamiento de tumores de cerebro con anticuerpos | |
AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
NO20092052L (no) | Antistoffer og immunkonjugater, og anvendelser derav | |
NO20092604L (no) | VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament. | |
EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
HK1243943A1 (zh) | 使用抗IL-1α抗體治療癌症 | |
CY1109468T1 (el) | Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια | |
MX2007012702A (es) | Uso de anticuerpos cd25 en inmunoterapia. | |
NO20056027L (no) | Surrogat terapeutisk endepunkt for anti-CTLA-4 basert immunoterapi av sykdom | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
NO20082381L (no) | Bispesifikke ligander med bindingsspesifisitet til celleoverflate mal og fremgangsmater for anvendelse derav | |
MX2009009787A (es) | Mutaciones de k-ras y terapia con anticuerpos anti-egfr. | |
MY147217A (en) | Antibody molecules having specificity for human il-06 | |
DE602005023488D1 (de) | Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie | |
CY1108645T1 (el) | Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη | |
ATE526037T1 (de) | Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
BRPI0921457A2 (pt) | anticorpo monoclonal ou fragmento do mesmo, métodos para tratar e para diagnosticar um paciente com câncer, ácido nucleico isolado, vetor isolado, e, célula hospedeira. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: WILEX AG (DE) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |